Compare Enveric Biosciences Inc (ENVB) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs McCormick & Company, Incorporated — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while McCormick & Company, Incorporated trades at $45.94 (market cap $12.39B). The key difference: McCormick & Company, Incorporated is far larger — about 1822.1× Enveric Biosciences Inc's market cap, and McCormick & Company, Incorporated pays a 4.18% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and McCormick & Company, Incorporated for 67 Days on average.
| ENVB | MKC | |
|---|---|---|
Market Cap | $6.80M | $12.39B |
Volume | 64,867 | 6,140,872 |
Sector | Health | Consumer Staples |
52-Week High | $10.80 | $71.65 |
52-Week Low | $1.27 | $44.14 |
Typical Hold Time | 14 Days | 67 Days |
Enterprise Value | -$1.49M | $17.07B |
Dividend Yield | — | 4.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
McCormick & Company (MKC) trades at $45.25, down 0.33% with a bearish technical signal despite strong Q3 2026 earnings that beat estimates. The stock shows attractive valuation metrics with a P/E of 8.18 and robust profitability including 19.39% net income margin. Recent performance reflects 17% sales growth driven by the Mexico acquisition and margin expansion, though technical indicators suggest near-term pressure with support at $44.
MKC presents a compelling value opportunity with below-sector P/E ratio and consistent dividend payments, though bearish technicals and mixed analyst sentiment (33% buy, 60% hold) indicate caution. Upside potential exists to the $53.50 consensus target, but investors face risks from integration challenges and macroeconomic pressure on consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
